131 related articles for article (PubMed ID: 3594716)
21. Response of lymphoid leukemia L1210 in mice to implantable sustained release cytosine arabinoside capsules.
Fu JC; Khwaja T; Moyer DL; Cummings L; Varvan J; Elshire D
J Surg Oncol; 1978; 10(1):1-7. PubMed ID: 628213
[TBL] [Abstract][Full Text] [Related]
22. Computer simulation of leukemia therapy: combined pharmacokinetics, intracellular enzyme kinetics, and cell kinetics of the treatment of L1210 leukemia by cytosine arabinoside.
Lincoln T; Morrison P; Aroesty J; Carter G
Cancer Treat Rep; 1976 Dec; 60(12):1723-39. PubMed ID: 1026330
[TBL] [Abstract][Full Text] [Related]
23. Enhancement of anti-tumor activity of 1-beta-D-arabinofuranosylcytosine by encapsulation in liposomes.
Kobayashi T; Kataoka T; Tsukagoshi S; Sakurai Y
Int J Cancer; 1977 Oct; 20(4):581-7. PubMed ID: 914397
[TBL] [Abstract][Full Text] [Related]
24. Treatment of L1210 murine leukemia with liposome-incorporated N4-hexadecyl-1-beta-D-arabinofuranosyl cytosine.
Schwendener RA; Schott H
Int J Cancer; 1992 May; 51(3):466-9. PubMed ID: 1592536
[TBL] [Abstract][Full Text] [Related]
25. Effect of 3-deazauridine on the metabolism, toxicity, and antitumor activity of azacitidine in mice bearing L1210 leukemia sensitive and resistant to cytarabine.
Li ZR; Campbell J; Rustum YM
Cancer Treat Rep; 1983 Jun; 67(6):547-54. PubMed ID: 6190558
[TBL] [Abstract][Full Text] [Related]
26. Immunospecific targeting of cytosine arabinonucleoside-containing liposomes to the idiotype on the surface of a murine B-cell tumor in vitro and in vivo.
Bankert RB; Yokota S; Ghosh SK; Mayhew E; Jou YH
Cancer Res; 1989 Jan; 49(2):301-8. PubMed ID: 2783380
[TBL] [Abstract][Full Text] [Related]
27. Enhanced retention of cytosine arabinoside and its metabolites and synergistic cytotoxicity by sequential treatment with dipyridamole in L5178Y leukemia.
Yang JL; White JC; Capizzi RL
Cancer Chemother Pharmacol; 1990; 26(2):135-8. PubMed ID: 2347039
[TBL] [Abstract][Full Text] [Related]
28. Effect of liposome size on peritoneal retention and organ distribution after intraperitoneal injection in mice.
Mirahmadi N; Babaei MH; Vali AM; Dadashzadeh S
Int J Pharm; 2010 Jan; 383(1-2):7-13. PubMed ID: 19729056
[TBL] [Abstract][Full Text] [Related]
29. Distribution and metabolism of lipsome-encapsulated and free 1-beta-D-arabinofuranosylcytosine (Ara-C) in dog and mouse tissues.
Ellens H; Rustum Y; Mayhew E; Ledesma E
J Pharmacol Exp Ther; 1982 Aug; 222(2):324-30. PubMed ID: 7097552
[TBL] [Abstract][Full Text] [Related]
30. Lymphatic absorption and tissue disposition of liposome-entrapped [14C]adriamycin following intraperitoneal administration to rats.
Parker RJ; Hartman KD; Sieber SM
Cancer Res; 1981 Apr; 41(4):1311-7. PubMed ID: 7214320
[TBL] [Abstract][Full Text] [Related]
31. Multivesicular liposomes containing 1-beta-D-arabinofuranosylcytosine for slow-release intrathecal therapy.
Kim S; Kim DJ; Geyer MA; Howell SB
Cancer Res; 1987 Aug; 47(15):3935-7. PubMed ID: 3607740
[TBL] [Abstract][Full Text] [Related]
32. Liposomal topotecan formulation with a low polyethylene glycol grafting density: pharmacokinetics and antitumour activity.
Li C; Wang C; Yang H; Zhao X; Wei N; Cui J
J Pharm Pharmacol; 2012 Mar; 64(3):372-82. PubMed ID: 22309269
[TBL] [Abstract][Full Text] [Related]
33. Multivesicular liposomes. Sustained release of the antimetabolite cytarabine in the eye.
Assil KK; Weinreb RN
Arch Ophthalmol; 1987 Mar; 105(3):400-3. PubMed ID: 3827719
[TBL] [Abstract][Full Text] [Related]
34. Liposomal Cytarabine as Cancer Therapy: From Chemistry to Medicine.
Salehi B; Selamoglu Z; S Mileski K; Pezzani R; Redaelli M; Cho WC; Kobarfard F; Rajabi S; Martorell M; Kumar P; Martins N; Subhra Santra T; Sharifi-Rad J
Biomolecules; 2019 Nov; 9(12):. PubMed ID: 31771220
[TBL] [Abstract][Full Text] [Related]
35. Effect of dose and schedule on pharmacokinetics of high-dose cytosine arabinoside in plasma and cerebrospinal fluid.
Slevin ML; Piall EM; Aherne GW; Harvey VJ; Johnston A; Lister TA
J Clin Oncol; 1983 Sep; 1(9):546-51. PubMed ID: 6583325
[TBL] [Abstract][Full Text] [Related]
36. Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia.
Kantarjian HM; Estey EH; Plunkett W; Keating MJ; Walters RS; Iacoboni S; McCredie KB; Freireich EJ
Am J Med; 1986 Sep; 81(3):387-94. PubMed ID: 3463209
[TBL] [Abstract][Full Text] [Related]
37. Characterization of tumor cell heterogeneity of a murine leukemia cell line (L1210) in response to arabinosylcytosine: quantitation using a computerized image analysis system.
Raymakers RA; Slocum HK; Minderman H; Malmberg M; Rustum YM
Exp Hematol; 1993 May; 21(5):602-7. PubMed ID: 8513859
[TBL] [Abstract][Full Text] [Related]
38. Use of liposomes for the enhancement of the cytotoxic effects of cytosine arabinoside.
Mayhew E; Papahadjopoulos D; Rustum YM; Dave C
Ann N Y Acad Sci; 1978; 308():371-86. PubMed ID: 279297
[No Abstract] [Full Text] [Related]
39. Modulation of the metabolism and pharmacokinetics of 1-beta-D-arabinofuranosylcytosine by 1-beta-D-arabinofuranosyluracil in leukemic mice.
Chandrasekaran B; Capizzi RL; Kute TE; Morgan T; Dimling J
Cancer Res; 1989 Jun; 49(12):3259-66. PubMed ID: 2720678
[TBL] [Abstract][Full Text] [Related]
40. [The effect of etoposide on influx and efflux of cytosine arabinoside in P388 murine leukemic cells].
Ooi K; Ohkubo T; Kuwabara H; Higashigawa M; Sakurai M
Yakugaku Zasshi; 1992 Nov; 112(11):832-6. PubMed ID: 1484348
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
